Publications by authors named "Silvia Torres-Manjon"
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.
J Immunother Cancer
March 2022
Background: VCN-01 is an oncolytic adenovirus (Ad5 based) designed to replicate in cancer cells with dysfunctional RB1 pathway, express hyaluronidase to enhance virus intratumoral spread and facilitate chemotherapy and immune cells extravasation into the tumor. This phase I clinical trial was aimed to find the maximum tolerated dose/recommended phase II dose (RP2D) and dose-limiting toxicity (DLT) of the intravenous delivery of the replication-competent VCN-01 adenovirus in patients with advanced cancer.
Methods: Part I: patients with advanced refractory solid tumors received one single dose of VCN-01.
Tumor targeting and intratumoral virus spreading are key features for successful oncolytic virotherapy. VCN-11 is a novel oncolytic adenovirus, genetically modified to express hyaluronidase (PH20) and display an albumin-binding domain (ABD) on the hexon. ABD allows the virus to self-coat with albumin when entering the bloodstream and evade neutralizing antibodies (NAbs).
View Article and Find Full Text PDFArticle Synopsis
- Retinoblastoma is a type of eye cancer found in kids that happens when genes that usually stop tumors aren't working.
- A special virus called VCN-01 is being tested to kill the cancer cells in retinoblastoma by targeting areas with messed-up genes.
- Early results show that VCN-01 can help fight the cancer and is safer than standard treatments, showing promise for future treatments without strong side effects.